MSI2 inhibitors, which have previously been tested in vitro in hematologic malignancies (Minuesa et al., 2019; Sureda-Gómez et al., 2023), should therefore be assessed in combination with radiation treatment. This evidence concerns the gene MSI2 and hematologic disorder.